Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01700504
Other study ID # 2012/0009
Secondary ID
Status Completed
Phase Phase 3
First received September 24, 2012
Last updated October 2, 2012
Start date May 2011
Est. completion date September 2012

Study information

Verified date September 2012
Source Hospital General Universitario Elche
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug AdministrationSpain: Comité Ético de Investigación Clínica
Study type Interventional

Clinical Trial Summary

The effect of axillary lavage with a gentamicin solution before wound closure will reduce the drainage volume and subsequently day of drainage removal.


Description:

Inclusion criteria will be a diagnosis of mammary neoplasms and plans to undergo an elective ALND of Berg´s levels I and II due to axillary metastasis determined preoperatively by core biopsy or evidence of metastasis in the SLNB in the intraoperative or in the differed analysis. Exclusion criteria will be chronic renal failure due to possible toxicity of gentamicin and patients undergoing a modified radical mastectomy.

The patients will be randomized by means of an Internet randomization module into 2 groups: those patients undergoing 2 lavages of the axillary surgical bed with normal saline (Group 1) and those ones first undergoing lavage with normal saline followed by a second lavage with a gentamicin solution (Group 2).

Surgical dissection will be performed using harmonic scalpel (Ultracision, Ethicon Endosurgery, Johnson and Johnson, Cincinnati, OH, USA). Once finished the ALND, a Jackson-Pratt drain will be left in place and connected to a low pressure vacuum device.

Methodology: Irrigation technique and extraction of microbiological samples:

The lavage will be performed immediately prior to closure of the wound, once placed the drainage into the cavity. In both groups, prior to the lavage, a microbiological sample from the surgical bed will be obtained with a swab (sample 1), followed by a lavage with 500 ml normal saline. After aspiration of the saline, a new microbiological sample will be obtained (sample 2). In Group 1 a second lavage with 500 ml normal saline will be performed, while in Group 2 the second lavage will be performed with an antibiotic solution, including gentamicin (240 mg) dissolved in 500 ml normal saline. After aspirating this second lavage, a third microbiological sample will be obtained in the same way as the two previous ones, in both groups (sample 3).

Indication of drain removal and obtention of sample 4:

After discharge, the patient will be asked to quantify the drainage volume daily. Drain will be removed when drainage volume was <30 ml/day. The drainage volume of the last day was collected in a syringe for microbiological study (sample 4).


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date September 2012
Est. primary completion date September 2012
Accepts healthy volunteers No
Gender Female
Age group 20 Years to 90 Years
Eligibility Inclusion Criteria:

- diagnosis of mammary neoplasms and plans to undergo an elective ALND of Berg´s levels I and II due to axillary metastasis determined preoperatively by core biopsy or evidence of metastasis in the SLNB in the intraoperative or in the differed analysis.

Exclusion Criteria:

- chronic renal failure due to possible toxicity of gentamicin

- patients undergoing a modified radical mastectomy.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention


Related Conditions & MeSH terms

  • Axillary Drainage Volume After Lymph Node Dissection.

Intervention

Drug:
Axillary lavage with gentamicin solution
Patients undergoing an axillary lavage with 500ml of normal saline followed by 500ml gentamicin solution

Locations

Country Name City State
Spain Hospital General de Elche Elche Alicante

Sponsors (1)

Lead Sponsor Collaborator
Hospital General Universitario Elche

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Drainage volume The drainage volumen between groups (interventional and control)will be analyzed. 7 days Yes